Anastrozole With or Without Gefitinib in Treating Postmenopausal Women With Metastatic or Locally Recurrent Breast Cancer

Breast Cancer Clinical Trial

Official title:

An EORTC Randomized, Double Blind, Placebo-Controlled, Phase II Multi-Center Trial Of Anastrozole (Arimidex) In Combination With ZD 1839 (Iressa) Or Placebo In Patients With Advanced Breast Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00066378
• Other study ID #: EORTC-10021
• Secondary ID: EORTC-10021IDBBC
• Status: Completed
• Phase: Phase 2
• First received: August 6, 2003
• Last updated: October 23, 2013
• Start date: May 2003

Study information

• Verified date: October 2013
• Source: European Organisation for Research and Treatment of Cancer - EORTC
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Federal Government
• Study type: Interventional

Clinical Trial Summary

RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using anastrozole may fight breast cancer by reducing the production of estrogen. Gefitinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Combining anastrozole with gefitinib may kill more tumor cells.

PURPOSE: Randomized phase II trial to compare the effectiveness of anastrozole with or without gefitinib in treating postmenopausal women who have metastatic or locally recurrent breast cancer.

Description:

OBJECTIVES:

• Compare the 1 year antitumor activity of anastrozole with vs without gefitinib, in terms of progression-free survival, in postmenopausal women with metastatic or locally recurrent advanced breast cancer.

• Compare the objective tumor response and duration of tumor response in patients treated with these regimens.

• Compare the progression-free survival of patients treated with these regimens.

• Compare the safety of these regimens in these patients.

OUTLINE: This is a randomized, double-blind, placebo-controlled, multicenter study. Patients are stratified according to participating center, dominant site of metastatic disease (bone alone vs other), prior chemotherapy (no vs yes), stage (metastatic vs locally recurrent), and measurability (measurable vs evaluable). Patients are randomized to 1 of 2 treatment arms.

• Arm I: Patients receive oral anastrozole and oral gefitinib once daily.

• Arm II: Patients receive oral anastrozole and an oral placebo once daily. In both arms, treatment continues in the absence of disease progression or unacceptable toxicity.

Patients are followed every 8 weeks until disease progression.

PROJECTED ACCRUAL: A total of 108 patients (54 per treatment arm) will be accrued for this study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 71
• Est. primary completion date: August 2007
• Accepts healthy volunteers: No
• Gender: Female
• Age group: N/A and older

Eligibility

DISEASE CHARACTERISTICS:

• Histologically confirmed breast cancer

• Radiologically or clinically evident metastatic or locally recurrent disease

• Locally advanced disease in elderly patients

• Bone metastases only allowed

• Failed prior tamoxifen therapy

• No rapidly progressive visceral metastases

• No uncontrolled CNS metastases

• Hormone receptor status:

• Estrogen receptor and/or progesterone receptor positive

PATIENT CHARACTERISTICS:

Age

• Postmenopausal

Sex

• Female

Menopausal status

• Postmenopausal, defined by any of the following:

• Natural menopause with last menses more than 1 year ago

• Radiotherapy-induced oophorectomy with last menses more than 1 year ago

• Chemotherapy-induced menopause with last menses more than 1 year ago AND serum follicle-stimulating hormone and luteinizing hormone and plasma estradiol levels clearly in the postmenopausal range

• Surgical castration

Performance status

• ECOG 0-2

Life expectancy

• Not specified

Hematopoietic

• Not specified

Hepatic

• Bilirubin no greater than 1.5 times upper limit of normal (ULN)

• Transaminases no greater than 2.5 times ULN

• No unstable or uncompensated hepatic disease

Renal

• No unstable or uncompensated renal disease

Cardiovascular

• No unstable or uncompensated cardiac disease

Pulmonary

• No unstable or uncompensated pulmonary disease

• No clinically active interstitial lung disease

• Asymptomatic chronic stable radiographic changes are allowed

Other

• No severe or uncontrolled systemic disease

• No other malignancy within the past 5 years except adequately treated carcinoma in situ of the cervix, nonmelanoma skin cancer, or contralateral breast cancer

• No psychological, familial, sociological or geographical condition that would preclude study compliance and follow-up

• No grade 2 or greater unresolved chronic toxicity from prior anticancer therapy

• No unresolved ocular inflammation or infection

• No known hypersensitivity to anastrozole or gefitinib or any of their excipients

PRIOR CONCURRENT THERAPY:

Biologic therapy

• No prior trastuzumab (Herceptin)

• No concurrent biologic therapy

Chemotherapy

• No more than 1 line of prior chemotherapy in the adjuvant or metastatic setting

• No concurrent chemotherapy

Endocrine therapy

• At least 2 years since prior aromatase inhibitors (e.g., anastrozole, letrozole, or exemestane) in the adjuvant setting

• Prior tamoxifen or fulvestrant in the adjuvant and/or metastatic setting allowed

• No prior aromatase inhibitors for metastatic disease

• No other concurrent hormonal therapy

Radiotherapy

• No concurrent radiotherapy to any metastatic site

Surgery

• No surgery during and within 4 days after the last dose of gefitinib

Other

• At least 30 days since prior investigational drugs

• No prior anti-epidermal growth factor therapy

• No prior anti-vascular endothelial growth factor therapy (i.e., tyrosine kinase inhibitor receptor)

• No concurrent administration of any of the following drugs:

• Phenytoin

• Carbamazepine

• Rifampin

• Phenobarbital

• Hypericum perforatum (St John's Wort)

• No other concurrent investigational drugs or treatment

• No other concurrent cancer treatment

• No concurrent systemic retinoids

• Concurrent bisphosphonate therapy for the treatment and prevention of bony metastases is allowed provided therapy was initiated prior to study entry

• Bisphosphonates may be initiated during study only for the treatment of hypercalcemia

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms

Intervention

Drug:
• anastrozole

• gefitinib

Locations

Country	Name	City	State
Belgium	Ziekenhuis Netwerk Antwerpen Middelheim	Antwerpen
Belgium	Institut Jules Bordet	Brussels
Belgium	Algemeen Ziekenhuis Sint-Augustinus	Wilrijk
France	Institut Bergonie	Bordeaux
France	Centre Henri Becquerel	Rouen
Netherlands	Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital	Amsterdam
Netherlands	Universitair Medisch Centrum St. Radboud - Nijmegen	Nijmegen
Slovenia	Institute of Oncology - Ljubljana	Ljubljana
United Kingdom	Edinburgh Cancer Centre at Western General Hospital	Edinburgh	Scotland

Sponsors (1)

Lead Sponsor	Collaborator
European Organisation for Research and Treatment of Cancer - EORTC

Countries where clinical trial is conducted

Belgium,  France,  Netherlands,  Slovenia,  United Kingdom, 

References & Publications (1)

Mauriac L, Cameron D, Dirix L: Results of randomized phase II trial combining Iressa (gefitinib) and arimidex in women with advanced breast cancer (ABC): EORTC protocol 10021. [Abstract] 31st Annual San Antonio Breast Cancer Symposium, December 10-14, 200

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression-free survival at 1 year		at 1 year	No
Secondary	Tumor response as measured by RECIST		from randomisation	No
Secondary	Duration of response as measured by RECIST		response duration	No
Secondary	Safety as measured by CTC v2.0		from randomization	Yes